NeoGenomics, Inc. specializes in cancer-focused genetic testing and diagnostics, serving a wide range of clients including hospitals, academic centers, and pharmaceutical companies primarily in the United States and the United Kingdom. The company offers a comprehensive suite of services such as cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, and molecular testing. These advanced diagnostic tools aid in understanding cancer at the genetic level, facilitating personalized treatment plans. Founded in 2001 and based in Fort Myers, Florida, NeoGenomics is dedicated to supporting oncology research and clinical practices with its cutting-edge testing capabilities.